文献速递新生儿儿童心血管与肾脏儿童呼吸

严重先天性肾病婴儿接受ECMO和肾脏支持治疗后的生存情况

Survival of Infants With Severe Congenital Kidney Disease After ECMO and Kidney Support Therapy.
PubMed 文献 · Pediatrics · 2024-01-01

本研究描述了5例先天性肾衰竭合并严重肺发育不良/肺动脉高压的新生儿,在接受ECMO和肾脏支持治疗后的长期结局。5例均在生后7天内接受肾脏支持治疗,ECMO持续时间4至23天,其中4例存活至今。存活的肺动脉高压患者病情缓解,3例已接受肾移植,1例等待移植评估。结论提示此类患儿不应再被默认判定为不可存活。

要点

  • 先天性肾衰竭合并严重肺发育不良/肺动脉高压的新生儿不应默认判定为不可存活。
  • 5例患儿均在生后7天内接受肾脏支持治疗,ECMO持续4至23天,4例存活。
  • 存活的肺动脉高压患者病情缓解,3例已接受肾移植,1例等待移植评估。

核心结论

  • 先天性肾衰竭合并严重肺发育不良/肺动脉高压的患儿不应再被反射性地判定为不可存活。
  • 精细的ECMO、呼吸、营养和肾脏支持治疗可能实现良好的长期结局。

研究设计与样本

  • 研究纳入2016年以来在阿拉巴马儿童医院NICU收治的31例先天性肾衰竭新生儿中的5例。
  • 5例因严重呼吸窘迫对常规干预无反应而接受ECMO,且均在生后9天内开始ECMO支持。
  • 研究描述了这5例患者的产前和产后诊断、ECMO过程、透析方式、并发症、手术及长期结局。

主要发现

  • 5例患儿均在生后7天内接受肾脏支持治疗。
  • 诊断包括后尿道瓣膜、双侧肾发育不良和常染色体隐性多囊肾病。
  • 胎龄范围为35.6至37.1周,出生体重范围为2740至3140克。
  • ECMO持续时间为4至23天,4例存活至今。
  • 存活患者中肺动脉高压缓解,3例无需氧疗,1例需夜间氧疗;3例已接受肾移植,1例等待移植评估。

临床怎么用

  • 对先天性肾衰竭合并严重肺发育不良/肺动脉高压的新生儿,不应默认判定为不可存活。
  • 可考虑精细的ECMO、呼吸、营养和肾脏支持治疗以争取良好长期结局。

局限性

  • 原文未报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Congenital kidney failure not only affects the homeostatic functions of the kidney, but also affects neonatal respiratory integrity. Until recently, extracorporeal membrane oxygenation (ECMO) support was not used in this population because the need for ECMO clearly established nonviability. Since 2016, 31 neonates have been admitted to the NICU at Children's of Alabama with congenital kidney failure. Five patients were placed on ECMO for severe respiratory distress unresponsive to conventional interventions. We evaluated neonates with congenital kidney failure and pulmonary hypoplasia/hypertension refractory to conventional therapies who received ECMO support within the first 9 postnatal days. We describe the pre and postnatal diagnoses, ECMO course details, dialysis modalities, complications, procedures, and long-term outcomes of these patients. All 5 patients received kidney support therapy by postnatal day 7. Diagnoses included posterior urethral valves, bilateral renal dysplasia, and autosomal recessive polycystic kidney disease. Gestational age ranged from 35.6 to 37.1 weeks. Birth weight ranged from 2740 to 3140 g. Days on ECMO ranged from 4 to 23. Four survived and are living today. Pulmonary hypertension resolved in surviving patients. Three surviving patients require no oxygen support, and 1 patient requires nocturnal oxygen. Three survivors received a kidney transplant, and 1 awaits transplant evaluation. Patients with congenital kidney failure with severe pulmonary hypoplasia/pulmonary hypertension no longer warrant a reflexive assignment of nonviability. Meticulous ECMO, respiratory, nutritional, and kidney support therapies may achieve a favorable long-term outcome. Further investigation of strategies for optimal outcome is needed.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Short K, McBride M, Anderson S, et al. Survival of Infants With Severe Congenital Kidney Disease After ECMO and Kidney Support Therapy. Pediatrics. 2024. PMID: 38303642. doi:10.1542/peds.2023-062717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。